The authors then tested the ability of pTP-TFE to bind to soluble tau in a confirmed AD patient and a confirmed patient with progressive supranuclear palsy (PSP), another ND that involves tau, and found that pTP-TFE colocalized with an antibody that detects phosphorylated tau in both patients (Figure 9). This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.